anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVE: Both bronchoscopic lung volume reduction with endobronchial valves (BLVR-EBV) and pulmonary rehabilitation (PR) are effective treatments for improving exercise capacity and patient-reported outcomes in patients with severe Chronic Obstructive Pulmonary Disease (COPD). According to current recommendations, all BLVR-EBV patients should have undergone PR first. Our aim was to study the effects of PR both before and after BLVR-EBV compared to BLVR-EBV alone.
METHODS: We included patients with severe COPD who were eligible for BLVR-EBV and PR. Participants were randomized into three groups: PR before BLVR-EBV, PR after BLVR-EBV or BLVR-EBV without PR. The primary outcome was change in constant work rate cycle test (CWRT) endurance time at 6-month follow-up of the PR groups compared to BLVR-EBV alone. Secondary endpoints included changes in 6-minute walking test, daily step count, dyspnoea and health-related quality of life.
RESULTS: Ninety-seven participants were included. At 6-month follow-up, there was no difference in change in CWRT endurance time between the PR before BLVR-EBV and BLVR-EBV alone groups (median: 421 [IQR: 44; 1304] vs. 787 [123; 1024] seconds, p = 0.82) or in any of the secondary endpoints, but the PR after BLVR-EBV group exhibited a smaller improvement in CWRT endurance time (median: 107 [IQR: 2; 573], p = 0.04) and health-related quality of life compared to BLVR-EBV alone.
CONCLUSION: The addition of PR to BLVR-EBV did not result in increased exercise capacity, daily step count or improved patient-reported outcomes compared to BLVR-EBV alone, neither when PR was administered before BLVR-EBV nor when PR was administered after BLVR-EBV.
An apparatus and method are provided that tracks patient recovery following an orthopedic procedure. A statistical computing engine implements a predictive model of the patient's post-procedural state for the orthopedic procedure based on a database of patient demographic data, comorbidities, pre-procedural walking parameters, including steps taken, and the orthopedic procedure that the patient is undergoing. The pre-procedural walking parameters are populated from physical sensor data automatically collected from the patient. The predictive model uses machine learning and is trained using training data sets. The predictive model creates a temporal trendline of post-procedural walking parameters, including steps taken, and a temporal trendline of post-procedural pain level. A processor then compares the patient's actual post-procedural state to the predictive model of the patient's post-procedural state. The post-procedural walking parameters are also obtained from the physical sensor.
PROBLEM TO BE SOLVED: To obtain the subject multiple unit type sustained release tablet that can reduce the deviation in elution rate caused by compression in the tabletting step and by the solubility of the active ingredient in water by admixing specific sustained release granule and powder part. SOLUTION: This pharmaceutical preparation contains the sustained release granules comprising the sustained release base coating core particles and the matrix of the active ingredient and the powdery part. As the sustained base, is preferably used ethyl cellulose, while the solvent for the base is preferably ethyl alcohol. The particle size of the active ingredient is adjusted to <=20μm on the average in order to increase its deposition rate on the core particles. Further, in order to reduce change in the elution rate caused by compression molding, the sustained release is further coated with a protective layer of water- soluble polymer on its outer taper.  Thus, the matrix is formed with a mixture of the sustained release base and the active ingredient (drug), differing from the granules coated with sustained release agent on the surface, after the conventional drug layer is coated, and so the matrix layer is not broken and the hardness of the tablets can be increased, when the powdery part is admixed and tabletted.
The subject matter described herein includes methods and systems for predicting and preventing negative behaviors with learning and AI algorithms. According to one method, physiological data of a user is measured. For example, using sensors located on the user. A stress level of the user is determined based on the measured physiological data. An intervention is then determined for adjusting the stress level of the user in response to the stress level being at least one of outside or nearing outside of a baseline range of the user. According to one system, at least one sensor measures physiological data of a user. An analysis device, such as a mobile device or remote server, determines a stress level of the user based on the measured physiological data and determines an intervention for adjusting the stress level of the user in response to the stress level being outside or nearing outside of a baseline range of the user.
Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.
This is a randomized, multicenter, clinical trial in which 598 patients with advanced gastric cancer at high risk of peritoneal metastases are randomly allocated to receive either preoperative hyperthermic intraperitoneal chemotherapy (HIPEC) plus gastrectomy (experimental group) or gastrectomy alone (control group). All patients, regardless of allocation, will additionally receive 4 cycles of FLOT chemotherapy (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 and 5-fluorouracil 2600 mg/m2) before surgery ± HIPEC and 4 cycles of FLOT chemotherapy after gastrectomy. The main outcome is frequency of peritoneal recurrence by 6-months post-operative. Patients will be followed for 5 years and undergo additional evaluations at 6 months, 1 year, 3 and 5 years.

The study will take place at 7 hospitals across Poland. All participating centers have the equipment and skills to perform all necessary procedures in this study. The below centers specialize in the treatment of stomach cancer with many documented years of experience. They are trained in the maintenance of a register, possess the skills to conduct appropriate research analyses and are equipped with a system for assessing the quality of both surgical and oncological treatment.
Metformin hydrochloride extended-release tablet is an oral antihyperglycemic medication used in the management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. The structural formula of metformin hydrochloride (metformin HCl) is as shown:

Metformin HCl, USP is a white to off-white crystalline compound with a molecular formula of C4H11N5•HCl and a molecular weight of 165.63. Metformin HCl, USP is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. Metformin hydrochloride extended-release tablets, USP are modified release dosage forms that contain 500 mg or 1,000 mg of metformin HCl. Each 500 mg tablet contains cellulose acetate, hydroxypropyl cellulose, FD&C blue #2, hypromellose, iron oxide black, lecithin, magnesium stearate, povidone, polyethylene glycol, polyvinyl alcohol, propylene glycol, sodium lauryl sulfate, talc, titanium dioxide, xanthan gum. Each 1,000 mg tablet contains cellulose acetate, hydroxypropyl cellulose, hypromellose, iron oxide black, lecithin, magnesium stearate, povidone, polyethylene glycol, polyvinyl alcohol, propylene glycol, sodium lauryl sulfate, talc, titanium dioxide, xanthan gum. Metformin hydrochloride extended-release tablets USP, 500 mg and 1,000 mg tablets are formulated to gradually release metformin to the upper gastrointestinal (GI) tract.
NEW MATERIAL:A compound shown by the formula I (R1 and R2 are methyl, or ethyl) and its pharmaceutically acceptable acid addition salt. EXAMPLE:2,4'-Dimethyl-3-piperidinopropionanilide. USE:A remedy for muscle spasm dolorosa caused by locomotorium deseases such as lumbago, backache, herniated disk, spondylitis doformans, etc. Having improved muscle relaxation, suppression of spinal reflex, anticonvulsive action, etc. PROCESS:A propenanilide derivative shown by the formula II is reacted with piperidine shown by the formula III in a solvent (e.g., ethanol, isopropanol, benzene, etc.) or in the absence of solvent to give a compound shown by the formula I . The reaction is carried out at room temperature -200 deg.C, preferably at 100-200 deg.C under heating.
The invention encmpasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon β, interferon γ, or granulocyte/macrophage colony stimulating factor. The composition may also include a second agent for treating cancer.
Creatinine (CR) is accepted as a clinical biomarker of chronic kidney disease (CKD) such as renal injury and kidney failure. To help facilitate the prognosis of CKD, a highly luminescent carbon dot (CD)-based fluorescent (FL) sensor has been built and employed for CR detection in diverse media (e.g., artificial and human urine). CDs, synthesized from sucrose precursor by a rapid microwave-assisted method (average diameter 20 nm), exhibited highly luminescent green emission upon UV exposure (λexcitation = 390 nm, λemission = 453 nm) with excellent temporal stability over three months. The nanocomposites are formed between CDs and metal ions (e.g., Cu2+) to realize the optimum biosensing of CR. Although Cu2+ ions showcases a maximum quenching (73 %) of the CDs, Cu2+/CDs system restores 77 % of the original FL intensity upon the addition of CR. The linear detection range and limit of detection for CR are estimated as 10-5 to 0.1 mg·dL-1 (R2 = 0.936) and 5.1 × 10-16 mg·dL-1, respectively. Furthermore, our biosensor shows excellent reproducibility and selectivity for CR in urine samples of healthy subjects and CKD patients. The Bland-Altman analysis for urine samples (n = 30) showcased an excellent agreement (R2 = 0.95) between our method and the gold standard 'Jaffe' method. These observations supported the practical utility of our method proposed for detection of CR in clinical samples.
Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% "B. Braun". The treatment will be given during CPR as soon as possible.
Two-week administration of telavancin in rats produced minimal renal tubular vacuolization with no changes in BUN or creatinine. These effects were not seen in studies conducted in dogs for similar duration. Four weeks of treatment resulted in reversible elevations in BUN and/or creatinine in association with renal tubular degeneration that further progressed following 13 weeks of treatment. 

These effects occurred at exposures (based on AUCs) that were similar to those measured in clinical trials. 

The potential effects of continuous venovenous hemofiltration (CVVH) on the clearance of telavancin were examined in an in vitro model using bovine blood. Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate [see Overdosage (10)].
Participants randomized to perform the by-phone hypnotizability test first. This will be followed within 1 week with the in-peron HIP test performed by a second, randomly-assigned investigator.
The investigators will conduct a pilot evaluation to understand the feasibility, acceptability, satisfaction and explore preliminary impacts of a preconception health program. The primary research question is: Is the preconception health program developed through the formative phase of this study acceptable and feasible to girls and caregiver participants? The program aims to improve the overall health and wellbeing of girls and their female caregivers by decreasing and delaying the initiation of substance use and risk behaviors associated with sexual initiation among adolescent girls. A second research question is: does the preconception health program have preliminary impacts on key protective and risk factors related to substance use and risky sexual behavior among girls and their female caregivers?

The Preconception Health Program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks. The total program duration is 660-990 minutes.

To adequately assess the primary research question, the investigators will enroll 60 dyads, grouped into three cohorts of 10 dyads each, who will complete satisfaction questionnaires after each of the program sessions and upon completion of the program. To assess preliminary impact on girls' risk for substance use and intention about sexual activity, including cultural connectedness, mother-daughter communication and psychological health and wellbeing, the investigators will deliver an evaluation conducted at baseline, upon completion of the intervention (post-intervention assessment) and 3 months following completion of the intervention (3-month follow-up assessment). The investigators will also assess program impact on female caregivers' substance use, parent-child communication and factors related to the female caregivers' wellbeing through an evaluation conducted at baseline, upon completion of the intervention (post-intervention assessment) and 3 months following completion of the intervention (3-month follow-up assessment).
PURPOSE:To obtain an anticoagulant capable of readily providing medical devices to be used especially in direct contact with blood with non-thrombogenic properties, comprising a complex of natural mucopolysaccharide and lipid. CONSTITUTION:A natural mucopolysaccharide (e.g. heparin) having anticoagulating action is blended with at least one lipid [e.g. phosphatidylcholine (lecithin)] selected from natural lipid and synthetic lipid in a weakly acidic buffer solution such as 2-(N-morpholino)ethanesulfonic acid under cooling with ice and lyophilized to give a natural mucopolysaccharide-lipid complex. Then the complex is dissolved in a solvent such as benzene, applied to the surface of medical devices by coating method, spray method, dip method, etc., dried and fixed. Consequently, medical devices can be provided with non-thrombogenic properties without causing reduction in mechanical strength of medical devices and damages such as hemolysis.
α-Melanocyte-stimulating hormone (α-MSH) regulates diverse physiological functions by activating melanocortin receptors (MC-R). However, the role of α-MSH and its possible target receptors in the heart remain completely unknown. Here we investigate whether α-MSH could be involved in pathological cardiac remodeling. We found that α-MSH was highly expressed in the mouse heart with reduced ventricular levels after transverse aortic constriction (TAC). Administration of a stable α-MSH analog protected mice against TAC-induced cardiac hypertrophy and systolic dysfunction. In vitro experiments revealed that MC5-R in cardiomyocytes mediates the anti-hypertrophic signaling of α-MSH. Silencing of MC5-R in cardiomyocytes induced hypertrophy and fibrosis markers in vitro and aggravated TAC-induced cardiac hypertrophy and fibrosis in vivo. Conversely, pharmacological activation of MC5-R improved systolic function and reduced cardiac fibrosis in TAC-operated mice. In conclusion, α-MSH is expressed in the heart and protects against pathological cardiac remodeling by activating MC5-R in cardiomyocytes. These results suggest that analogs of naturally occurring α-MSH, that have been recently approved for clinical use and have agonistic activity at MC5-R, may be of benefit in treating heart failure.
Complementary and alternative medicines (CAM) include conventional medical treatments. Patients worldwide use CAM at alarming rates; thus, reports of CAM-related DILI have been on the rise. The clinical presentations include asymptomatic liver test abnormalities, acute hepatitis with or without jaundice, acute cholestatic liver disease (bland or with hepatitis), acute liver failure, severe hepatitis with features of portal hypertension, and acute decompensation of known or unknown cirrhosis that can lead to acute-on-chronic liver failure. Acute hepatitis with or without necrosis, hepatocellular and canalicular cholestasis, herb-induced or CAM-triggered autoimmune hepatitis, granulomatous hepatitis, severe steatohepatitis, and vanishing bile duct syndrome are common liver biopsy findings in CAM-DILI. The presence of preexisting liver disease predicts severe liver injury, risk of progression to liver failure, and decreased transplant-free survival in patients with CAM-DILI. This review discusses global epidemiology and trends in CAM-DILI, clinical presentation, assessment and outcomes, commonly emerging threats in the context of hepatotoxic herbs, pragmatic assessment of "liver beneficial" herbs and health care myths, patient communication, regulatory framework, and future directions on research in CAM.
The present invention relates to a medicament for treating radioactive mucosal injury, recurrent aphthae and periodontitis, which relates to a medicament. In the prior art, the medicaments for effectively treating radiation injury in the oral mucous membrane, the pharyngeal mucous membrane and the esophageal mucous membrane by local medication are lacked. The medicament simultaneously comprises superoxide dismutase, vitamin B12 and vitamin B2 as ingredients. When the prepared product is an aerosol, the product comprises the components according to the dosage: 20000 to 100000 units of superoxide dismutase, 0.001 to 0.05 gram of vitamin B and 0.005 to 0.15 gram of vitamin B. When the prepared product is a buccal tablet, the prepared product comprises the components according to the dosage: 1000 to 4000 units of superoxide dismutase, 0.000009 to 0.00009 gram of vitamin B and 0.0002 to 0.0008 gram of vitamin B. The medicament has the advantages of extensive medicine source, low price, convenient preparation, convenient storage, convenient transportation and convenient use and carrying for patients, and a small amount of the medicament is enough to perform health care effects on the oral cavity and the whole body.
A double-blind randomized controlled clinical study of an 8-week intervention with 36 hypertensive subjects was carried out to evaluate the antihypertensive effect of fermented milk with Lactococcus lactis NRRL-B50571. Once obtained the informed consent; volunteers were randomized into two groups (n=18) to either receive 150 mL daily: fermented milk with Lactococcus lactis NRRL-B50571 (intervention group) or artificially acidified milk as control (placebo). Both drinks were consumed daily. Participants were asked not to change their diet or lifestyle during the intervention. We applied intention to treat for those participants who did not have good adherence and those who withdraw the study. The outcomes between groups were analyzed using an independent sample Student t test, with a P value of 0.05 or less (two sided) when there was statistical significance; using statistical software.
BACKGROUND: Pulmonary primitive neuroectodermal tumor (PNET), a member of the Ewing sarcoma family of tumors, is a rare malignancy that is associated with a grim prognosis. To date, fewer than 30 cases of pulmonary PNET have been reported. In this case report, we present the clinical details of a 12-year-old girl with pulmonary PNET who underwent surgical treatment. We also conducted an analysis and summary of other relevant studies and the surgical outcomes.
CASE PRESENTATION: In May 2018, a 12-year-old girl was admitted with symptoms of cough and blood-tinged phlegm. A computed tomography scan revealed a large mass, measuring 12.9 cm × 8.1 cm, in the right middle and lower lungs. A percutaneous lung biopsy confirmed poorly differentiated tumor cells with a nested growth pattern. Immunohistochemical staining demonstrated positive expression of CD99, CD56, Vimentin, and Synaptophysin. The patient was diagnosed with pulmonary PNET. Following three cycles of neoadjuvant chemotherapy, a substantial reduction in tumor volume was observed. Subsequently, the patient underwent a surgical procedure involving pneumonectomy and partial resection of the left atrium with the assistance of cardiopulmonary bypass. The patient was discharged 37 days after surgery. During a three-year follow-up period, she exhibited no signs of tumor recurrence and has successfully returned to school.
CONCLUSIONS: This case highlights the successful management of an advanced PNET with neoadjuvant chemotherapy, pneumonectomy, and partial resection of the left atrium employing cardiopulmonary bypass. The patient remained disease-free after three years. Our analysis of surgically treated cases indicates that neoadjuvant chemotherapy can contribute to improved prognoses for PNET patients. It is crucial to emphasize that complete surgical excision remains the cornerstone of treatment, underscoring the importance of surgeons considering radical surgical approaches whenever feasible for patients with pulmonary PNETs.